Teva buys Cephalon, beefs up branded business

Share this article:
Teva is buying Cephalon for $6.8 billion, thwarting a hostile takeover attempt by Valeant and bolstering the Jerusalem-based generics giant's footing in the market for branded pharmaceuticals.

Teva's purchase of outstanding Cephalon shares creates a branded portfolio worth $7 billion in sales through 20 products and gives the company entrée into pain management and oncology while adding to its respiratory and CNS franchises. The combined company will boast a branded product pipeline of more than 30 late-stage compounds, including several innovative compounds with blockbuster potential (Revascor, Lupuzor, Cinquil and Nuvigil for bipolar depression) and three candidates that are ready to file (Cephalon's Omapro and Teva's NOMAC and BDP Nasal), said Cephalon CEO Kevin Buchi.

“Clearly this acquisition is a game changer for Teva,” said Teva chief Shlomo Yanai. “We will now not only be the world's largest generics company, but also one of the world's largest specialty pharma companies. By combining Cephalon's strong marketed portfolio and pipeline of branded products with Teva's we will diversify and expand our offering in a way that accelerates and secures the future of our branded business.”

Teva said it expects to realize annual cost synergies of “at least $500 million in year three” after the deal closes, as it is expected to in the third quarter, though the firm offered no details as to where cuts might fall.

The deal, the company said, will help it realize its goal of growing its branded revenues from $4.6 billion in 2010 to more than $9 billion in 2015.

In March, Teva inked a global partnership with Procter & Gamble for OTC drugs. The companies said combining P&G's marketing muscle and retail access with Teva's global reach and pharmacy prowess would enable them to quadruple the $1 billion annual sales of their combined OTC businesses.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...